These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33397384)

  • 1. Histone methyltransferase SUV39H2 regulates LSD1-dependent CDH1 expression and promotes epithelial mesenchymal transition of osteosarcoma.
    Miao Y; Liu G; Liu L
    Cancer Cell Int; 2021 Jan; 21(1):2. PubMed ID: 33397384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retraction Note: Histone methyltransferase SUV39H2 regulates LSD1-dependent CDH1 expression and promotes epithelial mesenchymal transition of osteosarcoma.
    Miao Y; Liu G; Liu L
    Cancer Cell Int; 2023 Aug; 23(1):173. PubMed ID: 37596581
    [No Abstract]   [Full Text] [Related]  

  • 3. SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells.
    Piao L; Suzuki T; Dohmae N; Nakamura Y; Hamamoto R
    Oncotarget; 2015 Jul; 6(19):16939-50. PubMed ID: 26183527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone methyltransferase SUV39H2 serves oncogenic roles in osteosarcoma.
    Piao L; Yuan X; Zhuang M; Qiu X; Xu X; Kong R; Liu Z
    Oncol Rep; 2019 Jan; 41(1):325-332. PubMed ID: 30542727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SUV39H2 promotes colorectal cancer proliferation and metastasis via tri-methylation of the SLIT1 promoter.
    Shuai W; Wu J; Chen S; Liu R; Ye Z; Kuang C; Fu X; Wang G; Li Y; Peng Q; Shi W; Li Y; Zhou Q; Huang W
    Cancer Lett; 2018 May; 422():56-69. PubMed ID: 29458143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysine-specific demethylase 1 induced epithelial-mesenchymal transition and promoted renal fibrosis through Jagged-1/Notch signaling pathway.
    Zhang H; Xing J; Zhao L
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S203-S214. PubMed ID: 34396798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition.
    Lin T; Ponn A; Hu X; Law BK; Lu J
    Oncogene; 2010 Sep; 29(35):4896-904. PubMed ID: 20562920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressor of Variegation 3-9 Homolog 2, a Novel Binding Protein of Translationally Controlled Tumor Protein, Regulates Cancer Cell Proliferation.
    Kim AR; Sung JY; Rho SB; Kim YN; Yoon K
    Biomol Ther (Seoul); 2019 Mar; 27(2):231-239. PubMed ID: 30763986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LSD1 binds to HPV16 E7 and promotes the epithelial-mesenchymal transition in cervical cancer by demethylating histones at the Vimentin promoter.
    Liu Y; Wang Y; Chen C; Zhang J; Qian W; Dong Y; Liu Z; Zhang X; Wang X; Zhang Z; Shi X; Wu S
    Oncotarget; 2017 Feb; 8(7):11329-11342. PubMed ID: 27894088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LSD1 silencing inhibits the proliferation, migration, invasion, and epithelial-to-mesenchymal transition of hypopharyngeal cancer cells by inducing autophagy and pyroptosis.
    Wang H; Liu F
    Chin J Physiol; 2023; 66(3):162-170. PubMed ID: 37322626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of downstream metastasis-associated target genes regulated by LSD1 in colon cancer cells.
    Chen J; Ding J; Wang Z; Zhu J; Wang X; Du J
    Oncotarget; 2017 Mar; 8(12):19609-19630. PubMed ID: 28121627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2.
    Yang L; Ge D; Chen X; Qiu J; Yin Z; Zheng S; Jiang C
    Biochem Biophys Res Commun; 2018 Aug; 502(4):493-500. PubMed ID: 29859193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA-XIST promotes the oxidative stress-induced migration, invasion, and epithelial-to-mesenchymal transition of osteosarcoma cancer cells through miR-153-SNAI1 axis.
    Wen JF; Jiang YQ; Li C; Dai XK; Wu T; Yin WZ
    Cell Biol Int; 2020 Oct; 44(10):1991-2001. PubMed ID: 32515520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PRMT5-LSD1 axis confers Slug dual transcriptional activities and promotes breast cancer progression.
    Zhang J; Fan X; Zhou Y; Chen L; Rao H
    J Exp Clin Cancer Res; 2022 Jun; 41(1):191. PubMed ID: 35655230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LSD1-mediated epigenetic modification contributes to ovarian cancer cell migration and invasion.
    Li Y; Wan X; Wei Y; Liu X; Lai W; Zhang L; Jin J; Wu C; Shao Q; Shao G; Lin Q
    Oncol Rep; 2016 Jun; 35(6):3586-92. PubMed ID: 27109588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer.
    Yang J; Xu P; Chen Z; Zhang X; Xia Y; Fang L; Xie L; Li B; Xu Z
    Cancer Lett; 2023 Apr; 558():216092. PubMed ID: 36806557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automethylation of SUV39H2, an oncogenic histone lysine methyltransferase, regulates its binding affinity to substrate proteins.
    Piao L; Nakakido M; Suzuki T; Dohmae N; Nakamura Y; Hamamoto R
    Oncotarget; 2016 Apr; 7(16):22846-56. PubMed ID: 26988914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of SUV39H2 as a potential oncogene in lung adenocarcinoma.
    Zheng Y; Li B; Wang J; Xiong Y; Wang K; Qi Y; Sun H; Wu L; Yang L
    Clin Epigenetics; 2018 Oct; 10(1):129. PubMed ID: 30348215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis.
    Alsaqer SF; Tashkandi MM; Kartha VK; Yang YT; Alkheriji Y; Salama A; Varelas X; Kukuruzinska M; Monti S; Bais MV
    Oncotarget; 2017 Sep; 8(43):73372-73386. PubMed ID: 29088714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.